Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis
- 402 Downloads
To review the proportion of diabetic patients reaching recommended therapeutic goals, as reported in intervention trials and observational studies, and to analyse the factors associated with success or failure in achieving these targets.
A systematic review and meta-analysis through a Medline and Embase search for “diabetes” and “HbA1c” has been performed between 1 January 1995 and 1 March 2012 on randomised clinical trials and observational studies on type 1 (T1DM) or type 2 diabetes (T2DM) enrolling at least 200 patient*year.
Out of 169 patient groups in RCTs with results available for analysis, the overall proportion of patients reaching HbA1c ≤7 % was 36.6 (34.1–39.1) %. Of these, 8 groups included T1DM subjects [proportion at target (PAT) 27.2 (22.7–32.3) %] and 161 T2DM patients [PAT 37.1 (34.5–39.7) %]. In patients with T2DM on oral agents, at multivariate analysis, higher success rate was associated with higher age and body mass index (BMI), lower duration of diabetes, lower proportion of Caucasians and more recent publication year. Among the insulin treated, only duration of diabetes retained a significant association with success rate. Among 41 groups from cross-sectional studies, 6 and 22 were composed of patients with T1DM and T2DM, respectively, and the remaining 13 included both types. Patients at target for HbA1c were 19.8 (12.4–30.1), 36.1 (31.5–41.0), and 39.0 (32.9–45.3) %, respectively. Higher age, lower BMI, shorter duration of diabetes and a higher proportion of males and Caucasians were associated with a higher success rate.
Available data show that a wide distance remains between recommended targets and actual achievements in routine clinical practice.
KeywordsHbA1c targets Systematic review and meta-analysis Diabetes
Conflict of interest
Authors declare no conflicts of interest that might bias their work.
- 7.Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379PubMedCentralPubMedCrossRefGoogle Scholar
- 9.American Association of Clinical Endocrinologist (2007) Medical guidelines for clinical practice for the management of diabetes mellitus. http://www.aace.com
- 15.Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdóttir S, Eliasson B, Steering Committee of the Swedish National Diabetes Register (2007) Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 30(3):496–502PubMedCrossRefGoogle Scholar
- 23.Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group (2008) Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study. J Assoc Physicians India 56:859–863PubMedGoogle Scholar
- 25.Hanberger L, Samuelsson U, Lindblad B, Ludvigsson J, Swedish Childhood Diabetes Registry SWEDIABKIDS (2008) A1C in children and adolescents with diabetes in relation to certain clinical parameters: the Swedish Childhood Diabetes Registry SWEDIABKIDS. Diabetes Care 31(5):927–929 (Epub 2008 Jan 30)PubMedCrossRefGoogle Scholar
- 26.Pan CY, Ho LT, Soegondo S, Prodjosudjadi W, Suwanwalaikorn S, Lim SC, Chan TM, Chow KW, Thoenes M, Choi DS, DEMAND Study Investigators (2008) Prevalence of albuminuria and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective. Diabetes Technol Ther 10(5):397–403PubMedCrossRefGoogle Scholar
- 28.Cheung NW, Conn JJ, d’Emden MC, Gunton JE, Jenkins AJ, Ross GP, Sinha AK, Andrikopoulos S, Colagiuri S, Twigg SM, Australian Diabetes Society (2009) Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 191(6):339–344PubMedGoogle Scholar
- 30.Kaplan SH, Billimek J, Sorkin DH, Ngo-Metzger Q, Greenfield S (2010) Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care 48(6 Suppl):16 (Diabetes Res Clin Pract. 2006; 73(2):198–204)Google Scholar
- 48.Standards of Medical Care in Diabetes (2012) Diabetes Care 35:S11–S63Google Scholar